Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Skyhawk Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Skyhawk Therapeutics Expands its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

              Contact the Supplier

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Merck & Co. Inc.

              Deal Size: $600.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration May 12, 2020

              Details:

              Under the expanded collaboration, Skyhawk will deploy its SkySTARTM platform to develop drug candidates directed to multiple new targets for autoimmune and metabolic diseases. The collaboration now spans neurodegeneration, oncology, autoimmunity, and metabolic diseases.

              Almac Group

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Merck Taps Almac in Neurodegenerative Drug Discovery Deal

              Contact the Supplier

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Merck & Co. Inc.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 29, 2020

              Details:

              Research collaboration will focus on developing new small molecule inhibitors against specific targets of Deubiquitinase to treat a variety of neurodegenerative and other diseases.

              ProMIS Neurosciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates

              Contact the Supplier

              Lead Product(s): Antibody

              Therapeutic Area: Neurology

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 09, 2020

              Details:

              Data showing precision selectivity for neurotoxic TDP-43 and alpha-synuclein publishes in Neurology.

              PharmaCompass__DigitalAd